Search

You searched for "VUR"

378 results found

Priapism

7 January 2021 | | Andrology
Priapism is defined as an abnormally persistent erection lasting greater than four hours, not associated with sexual desire [1]. Although relatively uncommon with an incidence of 1.5 per 100,000 [2], priapism has a risk of complications which can have a...

LUTS update

8 January 2024 | | Functional Urology
Case study A 70-year-old, generally fit and well male attends your outpatient clinic. He has experienced a gradual deterioration in his voiding over the last few months. Specifically, he reports hesitancy, poor flow and nocturia. He denies visible haematuria. His...

Dietary citrate substitution in urolithiasis patients

1 July 2018 | | Endourology and Stones
Stone formation is dependent on supersaturation of urinary salts and urinary crystal retention. Urinary promoters (protein aggregates, cell debris) and inhibitors (citrate, magnesium, urinary macromolecules such as glycosaminoglycans and proteins) are involved in the process of stone formation [1]. Hypocitraturia...

Rotterdam Prostate Cancer Risk app

1 July 2014 | | Urologic Oncology, Technological Developments
The widespread use of prostate specific antigen (PSA) testing has led to diagnostic difficulties for patients and urologists. The sensitivity and specificity characteristics of PSA are far from optimal. To try and improve the predictive accuracy of PSA measurements, nomograms...

Improving on the Rotterdam Prostate Cancer Risk Calculator

1 January 2019 | | Technological Developments
Following the PROMIS trial [1], many cancer centres in the UK are now offering pre-biopsy multiparametric MRI (mpMRI) for men suitable for radical treatment. The European Association of Urology for Prostate Cancer (PCa) guidelines recommend individual risk stratification before the...

Biomarkers in prostate cancer detection

1 July 2018 | | Basic Science Research, Technological Developments, Urologic Oncology
Prostate cancer (PCa) is the second most common cancer in men with an estimated prevalence of 1.1 million worldwide in 2012. This heterogeneous disease resulted in approximately 307,000 deaths, making it the fifth leading cause of cancer-related death in men...

A greener urology

13 August 2020 | | Technological Developments
Healthcare in England is responsible for 4-5% of the country’s carbon footprint which is defined as the amount of greenhouse gasses, primarily carbon dioxide, released into the atmosphere by a particular activity. The six greenhouse gasses which vary in their...

Focal therapies in prostate cancer

1 November 2018 | | Technological Developments, Urologic Oncology
The standard of care in the management of prostate cancer has, to date, always been to treat the whole gland. This has ranged from surveillance, surgical excision / prostatectomy or external beam radiotherapy / whole gland brachytherapy. With the evolution...

Mitrofanoff Support – 2019 Report

11 December 2019
Mitrofanoff Support is a charity that serves 600 members from more than 20 countries, with more than 1,600 people on our closed Facebook group. As such, we can claim to be the largest support network of Mitrofanoffers in the world, and as awareness continues...

Penile Mondor’s disease

1 January 2019 | | Andrology
Mondor’s disease is a rare, self-limiting entity characterised by subcutaneous chord like bands throughout the body. These bands arise due to phlebitis of the subcutaneous vessels. Penile Mondor’s disease (PMD) is an isolated superficial thrombophlebitis of the superficial dorsal vein...

The management of renal calculi – Pt 2

1 May 2018 | | Endourology and Stones
Renal calculi can be managed according to four treatment options: conservative management, extracorporeal shock wave lithotripsy (ESWL), flexible ureterorenoscopy (FURS) and percutaneous nephrolithotomy (PCNL). Having addressed conservative management and ESWL in the last edition of Urology News, the second article...

Bladder cancer diagnosis and follow up: A new proven urinary biomarker to support the post COVID-19 recovery phase

7 September 2020
Since lockdown began most urologists have been following the advice of BAUS Oncology, to minimise the risk of exposure of patients and staff to potential COVID-19 infection: the result is an increasing backlog of patients requiring tests to determine if...